The cool solution.

It’s called stubborn fat on purpose. Because no matter how much pain you put into eating healthy and exercise, there’s no gain. It’s virtually impossible to lose that muffin top and those love handles. You’re forced to just live with them or think surgery. Which is not cool by us, and exactly why we developed CoolSculpting^®.

Here’s the skinny: developed by Harvard scientists, our unique, patented, clinically proven procedure involves freezing fat cells without damage to your skin. There’s no knife. No suction hoses. No needles. No lasers, even. After your treatment, you get on with your busy day.

Save up to $450 on your favorite fillers! Expires Dec 31, 2010

Save $450 on Restylane or Perlane

]]> http://www.skinperfectmedical.com/blog/archives/357/feed 0 http://www.skinperfectmedical.com/blog/archives/349 http://www.skinperfectmedical.com/blog/archives/349#comments Tue, 12 Oct 2010 07:04:25 +0000 admin http://www.skinperfectmedical.com/blog/?p=349 Continue reading →]]>

FDA Grants Market Clearance for Erchonia’s Zerona Laser

Proven safe and effective for circumference reduction of the waist, hips and thighs
McKinney, TX August 30, 2010 – Erchonia Corporation, the world’s leading manufacturer in low-level laser technology, has been granted market clearance by the U.S. Food and Drug Administration for the non-invasive body contouring device, the Zerona. The Zerona is the first non-invasive aesthetic device to receive FDA market clearance in the U.S. for circumferential reduction of the waist, hips, and thighs.

The FDA granted market clearance following the completion of a placebo-controlled, randomized, double-blind, multi-site clinical investigation evaluating sixty-seven study participants. The results obtained from that study demonstrated an average inch loss reduction of 3.65 inches across patient’s waist, hips, and thighs in as little as two weeks. The clinical trial, absent of diet restrictions, exercise requirements, or any other adjunctive components properly illustrated the clinical utility of the Zerona and set the precedent on how aesthetic devices should be evaluated. READ MORE…

Clinical Results Show Efficacy Benefit with Dysport™ for Treatment of Crow’s Feet

ALEXANDRIA, VA (SEPTEMBER 24, 2010)

At the American Academy of Facial Plastic and Reconstructive Surgery annual meeting, clinical results were presented demonstrating a significant efficacy advantage with Dysport™ (abobotulinumtoxinA) over Botox^® Cosmetic (onabotulinumtoxinA) for the treatment of Crow’s feet.  The data were presented Friday, September 24 at a scientific session at the AAFPRS 2010 Annual Fall Meeting, taking place September 23-26 in Boston.The 90-subject study, titled “Internally Controlled Double-Blind Comparison of Onabotulinum and Abobotulinum Toxin Type A (Nettar, Kartik D., M.D., et. al),” met its primary endpoint (p=0.01) of greater efficacy of action with Dysport™ as defined by investigator assessment of maximum contraction at Day 30 post injection compared to Day 0.  Additionally, a secondary endpoint—subject assessment at maximum contraction at Day 30 compared to Day 0—also demonstrated statistical significance with Dysport™ (p=0.027).

“Botox has long been considered the gold standard of injectables, so this data showing Dysport’s stronger efficacy is compelling,” said Corey S. Maas, M.D., F.A.C.S., AAFPRS Group Vice President for Public and Regulatory Affairs.  “Since injectables are the non-surgical cosmetic procedure rising fastest in popularity, it is important to continue honing new applications for existing treatments.  Dysport’s potential here is exciting as Crow’s feet are a common concern for many men and women.”

READ MORE…